Oncology

VBL Therapeutics Stops Development of its Psoriasis and Ulcerative Colitis Candidate and Focuses on its Lead Cancer Drug

Israel’s VBL Therapeutics announced that it does not plan to continue development of its VB-201 for treatment of patients with psoriasis and ulcerative colitis (UC). The company said that its Phase II studies evaluating its lead Lecinoxoid compound VB-201 in patients with psoriasis and UC did not meet their primary …

Read More »

New Affordable Care Act Initiative Aims to Improve Cancer Care and Cut Costs

Today, the US Department of Health and Human Services (HHS) announced a cancer care initiative for Medicare beneficiaries that will link payments to oncology practices to quality of care and patient outcomes. The New Affordable Care Act initiative, by the Centers for Medicare and Medicaid Services (CMS), is in support …

Read More »

Advaxis and Incyte Strike Cancer Immunotherapy Deal

Advaxis, Inc. has signed a deal with Incyte Corporation to evaluate the combination of the companies’ investigational cancer immunotherapies. The companies announced that they have entered into a clinical trial collaboration agreement to study the combination of Advaxis’ Lm-LLO cancer immunotherapy, ADXS-HPV (ADXS11-001), with Incyte’s oral indoleamine 2,3-dioxygenase 1 (IDO1) …

Read More »

GSK Reports Positive Results from its Late-Stage Melanoma Trial

GlaxoSmithKline (GSK) announced that its late-stage metastatic melanoma trial significantly improved overall survival (OS). The Phase III COMBI-d study evaluated the combination of the BRAF inhibitor, dabrafenib (Tafinlar), and the MEK inhibitor, trametinib (Mekinist), compared to single agent therapy with dabrafenib (Tafinlar) and placebo in patients with unresectable (Stage IIIC) …

Read More »

Ignyta’s Lung Cancer Drug Receives Orphan Drug Status from the FDA

Today, precision oncology biotechnology company Ignyta, Inc. announced that its lead candidate has been granted orphan drug designation from US health regulators. According to the company, the US Food and Drug Administration (FDA) granted Ignyta’s entrectinib orphan drug designation for the treatment of TrkA-positive, TrkB-positive, TrkC-positive, ROS1-positive and ALK-positive non-small …

Read More »

Roche’s Gazyva Succeeds in its Late-Stage Trial in Non-Hodgkin’s Lymphoma

Roche announced that it has ended its late-stage study evaluating its leukemia drug Gazyva earlier than expected following positive results. The company announced positive results from the Phase III GADOLIN study, which evaluated treatment options for patients with indolent non-Hodgkin’s lymphoma (NHL) who are refractory to MabThera/Rituxan (rituximab) treatment. After …

Read More »

Pfizer’s Breast Cancer Drug Receives Accelerated Approval from the FDA

Federal health regulators have provided an early approval to Pfizer Inc.’s Breakthrough breast cancer drug palbociclib. The company announced that the US Food and Drug Administration (FDA) has granted accelerated approval of Ibrance (palbociclib) in combination with letrozole, for the treatment of postmenopausal women with estrogen receptor-positive, human epidermal growth …

Read More »

Committee Recommends Continuation of CTI BioPharma’s Ovarian Cancer Study

Today, CTI Biopharma Corp. announced that an independent committee has recommended that the company continue its ovarian cancer study. The company said that the Gynecologic Oncology Group, now part of NRG Oncology, informed CTI that an independent Data Monitoring Committee (DMC) recommended continuation of the Phase III GOG-0212 clinical study, …

Read More »